Literature DB >> 23519950

Genomic profiling of cell lines for personalized targeted therapy for hepatocellular carcinoma.

Manjeet Deshmukh1, Yujin Hoshida.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23519950      PMCID： PMC4004055          DOI： 10.1002/hep.26407

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  6 in total

Review 1.  Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.

Authors:  Yujin Hoshida; Sara Toffanin; Anja Lachenmayer; Augusto Villanueva; Beatriz Minguez; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

2.  alpha-fetoprotein-producing hepatoma cell lines share common expression profiles of genes in various categories demonstrated by cDNA microarray analysis.

Authors:  H F Kawai; S Kaneko; M Honda; Y Shirota; K Kobayashi
Journal:  Hepatology       Date:  2001-03       Impact factor: 17.425

3.  Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer.

Authors:  Ju-Seog Lee; Snorri S Thorgeirsson
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

4.  Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro.

Authors:  Richard S Finn; Alexey Aleshin; Judy Dering; Peter Yang; Charles Ginther; Amrita Desai; Danyun Zhao; Erika von Euw; Ronald W Busuttil; Dennis J Slamon
Journal:  Hepatology       Date:  2013-04-01       Impact factor: 17.425

5.  The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Authors:  Jordi Barretina; Giordano Caponigro; Nicolas Stransky; Kavitha Venkatesan; Adam A Margolin; Sungjoon Kim; Christopher J Wilson; Joseph Lehár; Gregory V Kryukov; Dmitriy Sonkin; Anupama Reddy; Manway Liu; Lauren Murray; Michael F Berger; John E Monahan; Paula Morais; Jodi Meltzer; Adam Korejwa; Judit Jané-Valbuena; Felipa A Mapa; Joseph Thibault; Eva Bric-Furlong; Pichai Raman; Aaron Shipway; Ingo H Engels; Jill Cheng; Guoying K Yu; Jianjun Yu; Peter Aspesi; Melanie de Silva; Kalpana Jagtap; Michael D Jones; Li Wang; Charles Hatton; Emanuele Palescandolo; Supriya Gupta; Scott Mahan; Carrie Sougnez; Robert C Onofrio; Ted Liefeld; Laura MacConaill; Wendy Winckler; Michael Reich; Nanxin Li; Jill P Mesirov; Stacey B Gabriel; Gad Getz; Kristin Ardlie; Vivien Chan; Vic E Myer; Barbara L Weber; Jeff Porter; Markus Warmuth; Peter Finan; Jennifer L Harris; Matthew Meyerson; Todd R Golub; Michael P Morrissey; William R Sellers; Robert Schlegel; Levi A Garraway
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

6.  Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.

Authors:  Yujin Hoshida; Sebastian M B Nijman; Masahiro Kobayashi; Jennifer A Chan; Jean-Philippe Brunet; Derek Y Chiang; Augusto Villanueva; Philippa Newell; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Stacey Gabriel; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  Cancer Res       Date:  2009-09-01       Impact factor: 12.701
  6 in total
  7 in total

1.  Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition.

Authors:  Benjamin Schmidt; Lan Wei; Danielle K DePeralta; Yujin Hoshida; Poh Seng Tan; Xiaochen Sun; Janelle P Sventek; Michael Lanuti; Kenneth K Tanabe; Bryan C Fuchs
Journal:  Int J Cancer       Date:  2015-11-09       Impact factor: 7.396

2.  Molecular classification of hepatocellular carcinoma: potential therapeutic implications.

Authors:  Nicolas Goossens; Xiaochen Sun; Yujin Hoshida
Journal:  Hepat Oncol       Date:  2015

3.  Personalized management of hepatocellular carcinoma based on molecular information: future prospects.

Authors:  Nicolas Goossens; Yujin Hoshida
Journal:  Clin Liver Dis (Hoboken)       Date:  2015-06-01

4.  Clinicopathological indices to predict hepatocellular carcinoma molecular classification.

Authors:  Poh Seng Tan; Shigeki Nakagawa; Nicolas Goossens; Anu Venkatesh; Tiangui Huang; Stephen C Ward; Xiaochen Sun; Won-Min Song; Anna Koh; Claudia Canasto-Chibuque; Manjeet Deshmukh; Venugopalan Nair; Milind Mahajan; Bin Zhang; Maria Isabel Fiel; Masahiro Kobayashi; Hiromitsu Kumada; Yujin Hoshida
Journal:  Liver Int       Date:  2015-06-29       Impact factor: 5.828

5.  Expression and prognostic value of Ars2 in hepatocellular carcinoma.

Authors:  Qian He; Yongde Huang; Lei Cai; Shaobo Zhang; Chenghua Zhang
Journal:  Int J Clin Oncol       Date:  2013-11-23       Impact factor: 3.402

6.  In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment.

Authors:  Hadassa Hirschfield; C Billie Bian; Takaaki Higashi; Shigeki Nakagawa; Tizita Z Zeleke; Venugopalan D Nair; Bryan C Fuchs; Yujin Hoshida
Journal:  Exp Mol Med       Date:  2018-01-05       Impact factor: 12.153

7.  Aberrant AFP expression characterizes a subset of hepatocellular carcinoma with distinct gene expression patterns and inferior prognosis.

Authors:  Wei Chen; Jianjun Peng; Jinning Ye; Weigang Dai; Guanghua Li; Yulong He
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.